Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altavant Sciences Inc.

Division of Roivant Sciences Inc.
www.altavant.com

Latest From Altavant Sciences Inc.

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

Business Strategies Commercial

Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs

A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma. 

Financing Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Roivant Sciences Inc.
  • Senior Management
  • Bill Symonds, PharmD, CEO
    Lyn Baranowski, COO
    Larry Keller, MD, VP, Clinical Dev.
    James Bishop, VP, Strategic Dev. & Bus. Operations
    Steve Wring, PhD, VP, R&D
  • Contact Info
  • Altavant Sciences Inc.
    6501 Weston Pkwy.
    Ste. 330
    Cary, NC 27513
    USA
UsernamePublicRestriction

Register